Day: October 16, 2023

Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma

Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in […]

Continue Reading »

Atos Cloud Computing, the first authorized foreign-funded company to operate data centre and cloud computing services nationwide in China, renews its Value-Added Telecommunication Services licenses

Wuhan, China – October 16, 2023 – Atos has renewed its Value-Added Telecommunication Services licenses (VATS licenses) in China, enabling it to run world class digital services and data centers across the country. Atos Cloud Computing has retained the licenses since 2019, being the first authorized foreign-funded company to operate cloud computing VATS regulated activities […]

Continue Reading »

Smart City Expo to hold in 2023 its biggest edition ever

Smart City Expo World Congress BARCELONA, Spain, Oct. 15, 2023 (GLOBE NEWSWIRE) — Smart City Expo World Congress (SCEWC), the international summit on cities and smart urban solutions, organized by Fira De Barcelona, will hold its biggest edition to date in 2023. Taking place from November 7th to 9th, the event’s theme is “Welcome to […]

Continue Reading »

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS) Maintenance treatment with sonelokimab dosed every 4 weeks (Q4W), demonstrated that 57% of patients achieved HiSCR75 at week 24, increasing the landmark week 12 responses (primary endpoint) […]

Continue Reading »